Dresden University of Technology-ko ikertzaileekin lankidetzan egindako argitalpenak (2)

2007

  1. Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: Results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up

    Prostate Cancer and Prostatic Diseases, Vol. 10, Núm. 1, pp. 87-93

2001

  1. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression

    Urology, Vol. 58, Núm. 2, pp. 146-150